Vivus BV, a subsidiary of Vivus LLC, a biopharmaceutical company committed to the development and commercialization of innovative therapies that focus on advancing treatments for patients with serious medical conditions and life-limiting diseases, announced the new price reduction of QSIVA hard modified-release capsules phentermine/topiramate, is now in effect in Iceland. The lowered pricing structure is now available for 16,984 ISK per bottle at pharmacies throughout Iceland. The updated pricing reflects an average cost of 566.13 ISK per day, or considering the completer results on the top dose from the pivotal clinical trials, it is approximately 16,398 ISK per kilogram of weight loss.
An individual?s results may vary. According to the 2025 World Obesity Atlas, 22% of Icelandic adults live with obesity, and 59% of adults have a high body mass index (BMI). Excess body weight is associated with an increased risk of serious health conditions, including cardiovascular disease, stroke, and diabetes, which are among the leading causes of mortality.
Effective treatment options such as QSIVA can support patients in achieving and maintaining clinically meaningful weight loss, helping to improve long-term health outcomes and overall well-being. In the Phase III CONQUER trial, a 56-week clinical study, QSIVA demonstrated that subjects assigned to treatment achieved 7.8 ? 10.9% weight reduction (ITT analysis) and 7.6 ?
10.9 cm reduction of waist circumference after 56 weeks of treatment. Subjects who were treated with QSIVA for the full 56-week study period (completer on drug analysis) achieved 9.6 ? 14.4% weight reduction and 9.4 ?
13.6 cm reduction of waist circumference after completion of treatment. These clinical trials also demonstrated that phentermine/topiramate in combination with a weight-loss diet and exercise program resulted in statistically significant and clinically important reductions vs. placebo in weight and waist circumference, coupled with improvements in important risk markers indicative of weight-related comorbidities, such as systolic and diastolic BP, triglycerides, fasting glucose and progression towards type 2 diabetes.
QSIVA is available in the mid and top dose strengths evaluated in the Phase III CONQUER trial along with 2 other dose strengths. Dose selection should be individualized and determined by the treating physician based on patient characteristics, treatment response, and tolerability, in accordance with the approved prescribing information. QSIVA (the European brand name for QSYMIA) is approved in Sweden, Denmark, Finland, Iceland, and Poland.
QSIVA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol. The effect of QSIVA on reducing cardiovascular morbidity and mortality has not been established. The safety and effectiveness of QSIVA in combination with other products intended for weight loss, including prescription and over-the-counter drugs and herbal preparations, have not been established.
QSIVA hard modified-release capsules phentermine/topiramate is contraindicated in pregnancy and in women of childbearing potential not using highly effective contraception; in patients with glaucoma; in hyperthyroidism; in patients receiving treatment or within 14 days following treatment with monoamine oxidase inhibitors (MAOIs); in patients with hypersensitivity to sympathomimetic amines, to the active substances, or to any of the excipients in QSIVA. QSIVA can cause foetal harm. It is recommended that patients who can become pregnant obtain a negative pregnancy test result before starting QSIVA treatment, perform monthly pregnancy testing, and use highly effective contraception while taking QSIVA.
If a patient becomes pregnant while taking QSIVA, treatment should be discontinued immediately, and the patient should consult promptly with their doctor. The most common adverse reactions in adults are paraesthesia, dizziness, an altered or impaired sense of taste, insomnia, depression, constipation, and dry mouth.
